• Je něco špatně v tomto záznamu ?

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

BS. Adiwijaya, J. Kim, I. Lang, T. Csõszi, A. Cubillo, JS. Chen, M. Wong, JO. Park, JS. Kim, KM. Rau, B. Melichar, JB. Gallego, J. Fitzgerald, B. Belanger, I. Molnar, WW. Ma,

. 2017 ; 102 (6) : 997-1005. [pub] 20170605

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18016639

Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t1/2 ), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (Cmax ) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal-IRI was performed for tIRI and total SN-38 (tSN38) using patient samples from six studies. PK-safety association was evaluated for neutropenia and diarrhea in 353 patients. PK-efficacy association was evaluated from a phase III study in pancreatic cancer NAPOLI1. Efficacy was associated with longer duration of unencapsulated SN-38 (uSN38) above a threshold and higher Cavg of tIRI, tSN38, and uSN38. Neutropenia was associated with uSN38 Cmax and diarrhea with tIRI Cmax . Baseline predictive factors were race, body surface area, and bilirubin. Analysis identified PK factors associated with efficacy, safety, and predictive baseline factors. The results support the benefit of nal-IRI dose of 70 mg/m2 (free-base; equivalent to 80 mg/m2 salt base) Q2W over 100 mg/m2 Q3W.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18016639
003      
CZ-PrNML
005      
20180518092024.0
007      
ta
008      
180515s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cpt.720 $2 doi
035    __
$a (PubMed)28445610
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Adiwijaya, B S $u Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
245    10
$a Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer / $c BS. Adiwijaya, J. Kim, I. Lang, T. Csõszi, A. Cubillo, JS. Chen, M. Wong, JO. Park, JS. Kim, KM. Rau, B. Melichar, JB. Gallego, J. Fitzgerald, B. Belanger, I. Molnar, WW. Ma,
520    9_
$a Nanoliposomal irinotecan (nal-IRI) is a liposomal formulation of irinotecan with a longer half-life (t1/2 ), higher plasma total irinotecan (tIRI), and lower SN-38 maximum concentration (Cmax ) compared with nonliposomal irinotecan. Population pharmacokinetic (PK) analysis of nal-IRI was performed for tIRI and total SN-38 (tSN38) using patient samples from six studies. PK-safety association was evaluated for neutropenia and diarrhea in 353 patients. PK-efficacy association was evaluated from a phase III study in pancreatic cancer NAPOLI1. Efficacy was associated with longer duration of unencapsulated SN-38 (uSN38) above a threshold and higher Cavg of tIRI, tSN38, and uSN38. Neutropenia was associated with uSN38 Cmax and diarrhea with tIRI Cmax . Baseline predictive factors were race, body surface area, and bilirubin. Analysis identified PK factors associated with efficacy, safety, and predictive baseline factors. The results support the benefit of nal-IRI dose of 70 mg/m2 (free-base; equivalent to 80 mg/m2 salt base) Q2W over 100 mg/m2 Q3W.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a kamptothecin $x škodlivé účinky $x analogy a deriváty $x krev $x farmakokinetika $7 D002166
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a průjem $x chemicky indukované $7 D003967
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a liposomy $x škodlivé účinky $x krev $x farmakokinetika $7 D008081
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory $x krev $x farmakoterapie $x metabolismus $7 D009369
650    _2
$a neutropenie $x chemicky indukované $7 D009503
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kim, J $u Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
700    1_
$a Lang, I $u National Institute of Oncology, Budapest, Hungary.
700    1_
$a Csõszi, T $u JNSZ Megyei Hetényi Géza Kórház Rendelöintézet, Szolnok, Hungary.
700    1_
$a Cubillo, A $u Centro Integral Oncológico Clara Campal, Madrid, Spain.
700    1_
$a Chen, J-S $u Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan.
700    1_
$a Wong, M $u Westmead Hospital, Westmead, Australia.
700    1_
$a Park, J O $u Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
700    1_
$a Kim, J S $u Korea University Guro Hospital, Seoul, South Korea.
700    1_
$a Rau, K M $u Chang Gung Memorial Hospital Kaohsiung Branch, Kaohsiung, Taiwan.
700    1_
$a Melichar, B $u Onkologicka Klinika, Lekarska Fakulta Univerzity Palackeho a Fakultni Nemocnice, Olomouc, Czech Republic.
700    1_
$a Gallego, J B $u Hospital General de Elche, Elche, Spain.
700    1_
$a Fitzgerald, J $u Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
700    1_
$a Belanger, B $u Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
700    1_
$a Molnar, I $u Merrimack Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
700    1_
$a Ma, W W $u Mayo Clinic, Rochester, Minnesota, USA.
773    0_
$w MED00001155 $t Clinical pharmacology & therapeutics $x 1532-6535 $g Roč. 102, č. 6 (2017), s. 997-1005
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28445610 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20180518092202 $b ABA008
999    __
$a ok $b bmc $g 1300263 $s 1013479
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 102 $c 6 $d 997-1005 $e 20170605 $i 1532-6535 $m Clinical pharmacology & therapeutics $n Clin Pharmacol Ther $x MED00001155
LZP    __
$a Pubmed-20180515

Najít záznam

Citační ukazatele

Možnosti archivace